(NVCR)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
NovoCure Limited, onkologiya kompaniyasi, Qo'shma Shtatlar, Germaniya, Fransiya, Yaponiya, Buyuk Xitoy va xalqaro miqyosda qattiq o'simta saratonini davolash uchun o'simta davolash maydonlari (TTFields) qurilmalarini ishlab chiqish, ishlab chiqarish va tijoratlashtirish bilan shug'ullanadi. Uning TTFields qurilmalari Optune Gio, Optune Lua va Optune Paxni o'z ichiga oladi. Kompaniya shuningdek, miya metastazlari, oshqozon saratoni, glioblastoma, jigar saratoni, mayda hujayrali bo'lmagan o'pka saratoni, oshqozon osti bezi saratoni va tuxumdon saratonida TTFieldsni tekshiradigan klinik tadqiqotlarni olib bormoqda. NovoCure Limited 2000-yilda ro'yxatga olingan va shtab-kvartirasi Shveytsariyaning Baar shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Uri Weinberg M.D., Ph.D. | Chief Innovation Officer & Chief Medical Officer |
| Mr. Adam Daney | Head of Investor Relations |
| Mr. Barak Ben-Arye | General Counsel |
| Mr. Christoph Brackmann | Chief Financial Officer |
| Mr. Frank Leonard | Chief Executive Officer |
| Mr. Michael Puri | Chief Human Resources Officer |
| Mr. Mukund Paravasthu | Chief Operating Officer |
| Mr. William F. Doyle |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-12 | 8-K | nvcr-20260112.htm |
| 2025-12-01 | 8-K | nvcr-20251124.htm |
| 2025-10-30 | 8-K | nvcr-20251030.htm |
| 2025-09-15 | 8-K | nvcr-20250915.htm |
| 2025-08-28 | 8-K | nvcr-20250828.htm |
| 2025-07-24 | 8-K | nvcr-20250724.htm |
| 2025-06-30 | S-8 POS | s-8pos2025espp.htm |
| 2025-06-06 | 8-K | nvcr-20250604.htm |
| 2025-06-02 | 8-K | nvcr-20250531.htm |
| 2025-04-24 | 10-Q | nvcr-20250331.htm |
| Executive Chairman |